Genenta Science (NASDAQ:GNTA) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of Genenta Science (NASDAQ:GNTA) in a report published on Wednesday morning, Benzinga reports. They currently have a $25.00 price objective on the stock.

Genenta Science Price Performance

NASDAQ GNTA opened at $4.40 on Wednesday. Genenta Science has a 52-week low of $2.20 and a 52-week high of $5.87. The company has a fifty day moving average of $4.14 and a 200-day moving average of $3.67.

Institutional Trading of Genenta Science

A hedge fund recently bought a new stake in Genenta Science stock. AlTi Global Inc. purchased a new position in shares of Genenta Science S.p.A. (NASDAQ:GNTA) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned approximately 1.10% of Genenta Science as of its most recent filing with the Securities and Exchange Commission (SEC). 15.13% of the stock is owned by hedge funds and other institutional investors.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.